{"id":"W3089163327","doi":"10.1016/j.annonc.2020.08.2079","title":"685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma Global Development; EMD Serono; Genentech; Sanofi; BeiGene; Gilead Sciences; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Placebo; Urology; Gynecology; Hazard ratio; Oncology; Prostate-specific antigen; Cancer; Confidence interval; Androgen receptor; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000659768,0.001442527,0.001957279,0.0004608677,0.0003943072,0.0006373343,0.0006735634,0.001270779,0.008198639],"category_scores_gemma":[0.0007991628,0.0005294335,0.001043259,0.0003849202,0.0007301728,0.0005646018,0.0002685092,0.002037036,0.00104416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005300003,"about_ca_system_score_gemma":0.001263453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001992208,"about_ca_topic_score_gemma":0.004244504,"domain_scores_codex":[0.9996859,0.0001527167,0.00001486637,0.00005469484,0.00002567243,0.00006623538],"domain_scores_gemma":[0.9996535,0.00008357219,0.00005569722,0.00002184096,0.00002575557,0.0001597137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.964011,0.005942977,0.000646679,0.0005274251,0.0005916983,0.00003570451,0.00003413127,0.0002631793,0.004965266,0.0001273577,0.00100496,0.02184953],"study_design_scores_gemma":[0.9467186,0.04976076,0.001726435,0.00002211436,0.0002748574,0.00002048668,0.00001280985,0.0002483125,0.000418871,0.00007776458,0.0007089897,0.00001002814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981603,0.004085532,0.001124597,0.0006518979,0.0003999475,0.004840683,0.002399242,0.0003407765,0.004554432],"genre_scores_gemma":[0.980179,0.003016084,0.002667401,0.001564154,0.0002755836,0.004580534,0.00221443,0.00004716374,0.005455574],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008198639,"threshold_uncertainty_score":0.0274272,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1158635947186557,"score_gpt":0.4313768723674121,"score_spread":0.3155132776487564,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}